JDRF-Backed Start-Up Company to Accelerate Work Through Pfizer
AnTolRx, Inc., a private biotechnology company, has agreed to license its immune tolerance therapy for type 1 diabetes (T1D) to Pfizer with the aim of advancing the research and accelerating its potential for commercialization. The research is part of a larger portfolio of work done by AnTolRx, a Cambridge, Massachusetts-based research and development biotechnology company. […]
Eli Lilly Announces Lower-Cost Generic Insulin
Eli Lilly and Company announced it will begin selling a generic version of its most commonly prescribed insulin -- Humalog
Can a Snail Hold the Key to Better Blood Sugar Control?
Helena Safavi, Ph.D., of The University of Utah, decided to take an unusual and creative approach to ultra-rapid insulin development, studying sea snails that use fast-acting insulin, not as a hormone to regulate their blood glucose, but as a toxin to sedate their prey.
Tracking Oxygen Levels Around Transplanted Cells Could Help Build Successful Beta Cell Replacement Therapies
Understanding change in oxygen levels over time in mice may help researchers develop better methods of replacing beta cells in humans.
In First-In-Human Tests, New Artificial Pancreas System Smartphone App Shows Reliable Glucose Control
Artificial pancreas (AP) systems “close the loop” between continuous glucose monitors and insulin pumps using algorithms to manage insulin. Learn more about Breakthrough T1D's funding of groundbreaking AP technology research.
Breakthrough T1D-Funded Researchers Reprogram Human Alpha Cells to Produce Insulin
Human cells, including pancreatic islet cells, are more adaptive than previously believed. Led by Dr. Pedro Herrera at the University of Geneva, Breakthrough T1D-funded researchers demonstrated that transplanted alpha and gamma cells could produce insulin and reverse diabetes in mice.
Multiple Benefits of Screening For Beta Cell Autoimmunity in Children
Learn more about Breakthrough T1D’s prevention research and the benefits of early detection for type 1 diabetes (T1D).
Stem Cells to Beta Cells for Insulin Therapy: One Step Forward by Breakthrough T1D-Funded Researchers
Scientists have made a significant advancement in beta cell replacement research, potentially eliminating the need for insulin therapy for people with type 1 diabetes (T1D). This novel approach could pave the way for effective beta cell replacement therapies, offering hope for those with T1D.
ATTD Conference Brings Together Top Minds in Diabetes Research
Join diabetes researchers from around the world at the annual Advanced Technologies & Treatments for Diabetes (ATTD) conference. Breakthrough T1D-funded research will be featured, with 23 funded researchers presenting.
FDA Approval Means More Choices for our T1D Community
The FDA approves the first interoperable insulin pump, the t:slim X2™ by Tandem Diabetes Care.
